Key Findings
Alcon announced the acquisition of Neurotech Pharmaceuticals on October 20, 2026, for an upfront payment of $550 million, with additional contingent payments tied to commercial milestones. The primary asset acquired is revakinagene taroretcel-lwey (Encelto), an encapsulated cell therapy for adults with idiopathic macular telangiectasia type 2 (MacTel). Alcon expects the transaction to be modestly accretive to net sales growth, though it may slightly dilute core diluted earnings per share in 2027 before becoming accretive thereafter.
Technical Details
Encelto is a cell-based gene therapy that utilizes a semipermeable capsule containing allogeneic retinal pigment epithelium cells. These cells are genetically engineered to continuously release recombinant human ciliary neurotrophic factor, a protein designed to protect retinal cells and reduce photoreceptor loss. The device is surgically implanted intravitreally.
The therapy’s efficacy was evaluated in two randomized, sham-controlled phase 3 trials (NTMT-03-A and NTMT-03-B) involving 228 participants over 24 months. The primary endpoint was the rate of ellipsoid zone loss:
- NTMT-03-A: Loss was 0.075 mm² in treated eyes vs 0.166 mm² in sham eyes (p<.001), representing a 54.8% reduction.
- NTMT-03-B: Loss was 0.111 mm² in treated eyes vs 0.160 mm² in sham eyes (p=.02), representing a 30.6% reduction.
The National Eye Institute noted that results for retinal sensitivity and reading speed were mixed across the two trials.
Background & Context
MacTel is a bilateral, neurodegenerative retinal disease causing progressive central vision loss and retinal blood vessel changes. Alcon estimates that 25,000 patients in the US are diagnosed with the condition, with 2,000 to 3,000 new diagnoses annually. Encelto received FDA approval on March 5, 2025, following priority review and orphan drug designation, filling a significant unmet need as the first approved treatment for the disease.
Significance & Outlook
The acquisition integrates Neurotech’s cell therapy platform with Alcon’s global clinical expertise and commercial reach. However, limitations include the requirement for surgical implantation and inconsistent functional outcomes across phase 3 trials. Alcon has not yet disclosed a timeline for seeking approval outside the United States.
Source: https://www.biopharminternational.com/view/alcon-550-million-neurotech-mactel-cell-therapy
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
